Akero Therapeutics Inc (NASDAQ:AKRO) currently has a daily average trading volume of 1.40M but it saw 1562533 shares traded in last market. With a market cap of 1.74B USD, the company’s current market price of $25.19 came falling about -2.55 while comparing to the previous closing price of $25.85. In past 52 weeks, the stock remained buoying in the range of price level as high as $58.38 and as low as $11.25.
Taking a look at 20-day trading activity of Akero Therapeutics Inc (AKRO) gives us an average price of $27.75, while its current price level is -56.85% below from 52-week high level whereas it is 123.91% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $24.01 while that of 200 days or SMA-200 reads an average of $32.34. A closer look into the stock’s movement over the week reveals that its volatility is standing at 8.70% during that period while stretching the period over a month that increases to 10.39%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 45.20 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Cantor Fitzgerald which initiated the stock as “Overweight” in its note to investors issued on September 19, 2023, recommending a price target of $69 for it. Morgan Stanley issued its recommendations for the stock as it upgraded the price target for the stock in the range of between $40 and $65.
Over the week, AKRO’s stock price is moving -9.94% down while it is 16.51% when we observe its performance for the past one month. Year-to-date it is 7.88% up and over the past year, the stock is showing a downside performance of -33.90%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2023, when its quarterly earnings per share (EPS) of -$0.99 beaten by the consensus estimate of -$0.86 for the same. For AKRO, analysts are forecasting an EPS-growth rate of -37.40% for current year and estimate for EPS growth in next year is -9.10%.
Currently, Akero Therapeutics Inc’s total number of outstanding shares is 68.95M with 5.92% of that held by the insiders while 94.46% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -27.05% and return on equity (ROE) at -35.22%. Stock’s beta reads -0.37. Stock has a price to book (P/B) ratio of 2.62. Its return on asset (ROA) is -32.40% on average.
